Short acting GLP-1 receptor agonist (injectable)
Lixisenatide 20 µg injection twice daily
LIXI_SC_20UG_BID
Related
- All doses pooled: Lixisenatide injection
- Lixisenatide 20 ug subcutaneous once daily
- Lixisenatide 5 µg injection once daily
- Lixisenatide 10 µg injection once daily
- Lixisenatide 30 µg injection once daily
- Lixisenatide 5 µg injection twice daily
- Lixisenatide 10 µg injection twice daily
- Lixisenatide 30 µg injection twice daily
- Lixisenatide 10 µg injection
- Lixisenatide 2.5 µg injection
- Lixisenatide 5 µg injection
- Lixisenatide 20 µg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.79 (0.01 to 63.33) | 0.41 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 4.50 (0.76 to 20.65) | 0.19 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.48 (0.23 to 6.86) | 0.36 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.78 (1.62 to 8.46) | 0.36 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.68 (1.55 to 19.35) | 0.28 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.28 (0.47 to 3.19) | 0.59 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.92 (0.05 to 14.89) | 0.45 |